Oxford Biomedica (LON:OXB) Sets New 12-Month Low – Here’s Why

Oxford Biomedica plc (LON:OXB)’s share price reached a new 52-week low on Thursday. The stock traded as low as GBX 367.50 and last traded at GBX 569.37, with a volume of 253,422 shares trading hands. The stock had previously closed at GBX 552.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and issued a GBX 595 target price on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a GBX 900 price objective on shares of Oxford Biomedica in a research note on Tuesday, September 1st. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a GBX 827 price objective on shares of Oxford Biomedica in a report on Monday, October 26th. Three investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 818.

Oxford Biomedica Trading Up 3.1%

The company has a fifty day simple moving average of GBX 500.71 and a two-hundred day simple moving average of GBX 603.54. The company has a current ratio of 2.21, a quick ratio of 1.67 and a debt-to-equity ratio of 273.08. The company has a market cap of £688.64 million, a PE ratio of -17.80 and a beta of 1.11.

Oxford Biomedica (LON:OXB) last posted its quarterly earnings results on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative net margin of 23.23% and a negative return on equity of 54.51%. Analysts anticipate that Oxford Biomedica plc will post -31.08 EPS for the current year.

Insiders Place Their Bets

In other news, insider Roch Doliveux purchased 20,250 shares of the stock in a transaction on Wednesday, September 23rd. The stock was bought at an average price of GBX 505 per share, for a total transaction of £102,262.50. 25.83% of the stock is currently owned by company insiders.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.